HOME >> BIOLOGY >> NEWS
Progress toward a new remedy for chronic urinary tract infections?

Brussels, Belgium - Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) at the Free University of Brussels have recently published results that show promise in the quest for a new remedy for chronic urinary tract infections. The researchers have shown that administration of the sugar Heptyl--D-mannoside can prevent E. coli bacteria from binding to the wall of the urinary tract - which is the first step in the development of the infection.

A widespread problem

Urinary tract and bladder infections are among the most prevalent bacterial infections and can be quite painful. Fifty percent of all women are confronted by these unpleasant infections at some point in their lives. The disorder is an especially severe problem when it becomes chronic - whereby some patients experience symptoms almost continually. The Escherichia coli bacterium is responsible for 80% of these urinary tract infections. Treatment with antibiotics is possible but does not preclude a recurrence of the infection. In addition to this, more and more bacteria are becoming resistant to the antibiotics. For these reasons, scientists have been busy seeking another solution.

Prevention is better than cure

Julie Bouckaert and her co-researchers, under the direction of Henri De Greve, have discovered a way to prevent E. coli bacteria from adhering to the wall of the urinary tract, so that they can no longer cause infection. Because E. coli bacteria use very particular hair-like projections (called pili) to cling to tissues - the first stage of a potential inflammation - a drug that can prevent this attachment can also avert bladder and urinary tract inflammations.

Combating certain bonds

Bouckaert and De Greve have investigated the way in which the E. coli bacteria attach themselves. This attachment takes place by means of a reaction between the protein 'Adhesine FimH' on the tips of the pili and special receptor
'"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
10-Feb-2005


Page: 1 2

Related biology news :

1. Breast cancer milieu -- Progression, tamoxifen sensitivity, and DNA reversion
2. Progress toward a targeted therapy for a specific form of leukemia
3. Progress against sarcoma
4. Progress toward artificial photosynthesis?
5. 2nd annual Albert Szent-Gyrgyi Prize for Progress in Cancer Research awarded to Webster K. Cavenee
6. Progress in battle against life-threatening acute allergy
7. Progress report on Homogeneous Assay project
8. Progress being made in exploring potential use of stem cells to treat heart disease
9. Media Invite: Dinner to award prize for Progress in Cancer Research
10. Progress needed on global regime for access to genetic resources and benefit-sharing
11. Albert Szent-Gyrgyi Prize for Progress in Cancer Research announced

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/19/2016)... , España y TORONTO , 19 de diciembre ... Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un ... en varios tipos de tumor en 2017, con múltiples sitios previstos ... ... clase con objetivo en el factor inhibidor de leucemia (LIF), una ...
(Date:12/15/2016)... VANCOUVER, Canada and BADEN-BADEN, Germany ... Solutions, a leading global financial services provider, today announced an ... in passive behavioural biometrics, to join forces. The partnership will ... fraud mitigation strategies in compliance with local data protection regulation. ... In ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017  Caris Life Sciences, ... Lustgarten Foundation, the largest private funder of pancreatic ... trial evaluating the impact of immunotherapy in the ... trial enrollment services to identify potential trial candidates ... between treating physicians and study investigators. The Lustgarten ...
(Date:1/17/2017)... Foreside, Maine (PRWEB) , ... January 17, 2017 ... ... announce the addition of Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration verification ... Rheumatoid Factor in a human serum base. Each VALIDATE® SP2 kit is prepared ...
(Date:1/17/2017)... , Jan. 17, 2017  An international team ... Medicine and St. Boniface Hospital Albrechtsen Research Centre/University ... neuropathy, an unmet health need affecting nearly one ... of Clinical Investigation, their results identify small molecule ... and reverse neuronal injury in animal models of ...
(Date:1/17/2017)... LEXINGTON, Mass. , Jan. 17, 2017   ... clinical stage biopharmaceutical company developing innovative inhaled therapies to ... candidate for treating fungal infections in the lungs of ... Infectious Disease Product" (QIDP) by the U.S. Food & ... , which is designed to speed the development of ...
Breaking Biology Technology:
Cached News: